fashion -WSS

fashion

author：leisure time 2025-09-30 00:45:42 - browse：1642

A judge ruled that Welsh Carson won't have to face antitrust allegations about its anesthesiology practice. Adobe

Welsh, Carson, Anderson & Stowe has wiggled out of the grasp of the Federal Trade Commission, but the private equity firm’s anesthesia company, U.S. Anesthesia Partners, still must face the agency’s antitrust case, a judge ruled last week.

The FTC alleged last year that the anesthesiology network monopolized markets in Texas to drive up prices, but took the unusual step of attaching Welsh Carson as a defendant with USAP. Dismissing Welsh Carson from the case was a victory for the private equity firm and, more broadly, other firms worried that the Biden administration would try to hold them responsible for anything their portfolio companies do.

But the allegations against USAP didn’t disappear, which will keep up scrutiny on companies that have made a push to acquire numerous physician groups.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Test for long Covid? Researchers find new clue in blood samples

WSS

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

FDA clears AI tool for detecting skin cancer

NIH director takes cautious approach to Biden drug pricing priority

Copay coupons to count toward deductibles, after Biden court move

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

The surgeon had a dilemma only a Nazi medical text could resolve

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+.

entertainment

In Memoriam: Notable people who died in 2023

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Hollywood unions extend contract negotiations for actors

Think you might have Covid

Apple is now the first public company to be valued at $3 trillion

The tragedy of Johnson & Johnson’s Covid vaccine

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Parkinson’s finding may lead to tests and, someday, treatments

Apple is now the first public company to be valued at $3 trillion

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

focus

Test for long Covid? Researchers find new clue in blood samples

Dewpoint Therapeutics lays off staff after losing partnerships

Parkinson’s finding may lead to tests and, someday, treatments

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

How digital therapeutics firms are pivoting after Pear's bankruptcy

Test for long Covid? Researchers find new clue in blood samples

entertainment

entertainment

entertainment

entertainment